- Top Workplaces
- CTMC
CTMC
CTMC was formed in May 2022 as a spin-off from the Biologics Development Division of MD Anderson Cancer Center. We are a joint venture between Resilience and MD Anderson to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.
Our unique biotech-friendly model offers more than the standard end-to-end capabilities through our collaborative process. Uniting the strengths of Resilience and MD Anderson, CTMC enables smaller organizations to robustly reach clinical proof of concept and be flexibility positioned for commercialization.
Our unique biotech-friendly model offers more than the standard end-to-end capabilities through our collaborative process. Uniting the strengths of Resilience and MD Anderson, CTMC enables smaller organizations to robustly reach clinical proof of concept and be flexibility positioned for commercialization.